Mortality and morbidity of pregnant woman with COVID- 19 Infection : A meta analysis

Aida Musyarrofah, Anung Putri Illahika, Probo Yudha Pratama Putra, Dinda Amalia Eka Putri, S.Khansa Zatalini, Yohanes Eddy Prasetyo

Abstract


Coronavirus disease 2019 (COVID-19) is caused by SARS-CoV-2 and declared as a global pandemic in March 2020. There is a special immune tolerance in pregnant woman, predisposes to a viral infection, then increased risk severe complication. A comprehensive literature study was performed in July 2021 through Science Direct, Cochrane, and PubMed, with keywords “COVID-19”, “SARS-CoV-2”, “Pregnancy”, “Pregnant”, and “Complication”. Nine studies with 30.257 infected patients and 1.678.974 non infected patients were included. The data show that preterm birth (OR=1.43, 95% CI: 1.17-1.74; p = 0.0004, I2=90%) less in non infected groups, no camparable finding in vaginal delivery (OR =0.93, 95% CI: 0.82-1.06; p<0.030, I2=75%) and caesarian delivery (OR =1.07, 95% CI: 0.90-1.28; p<0.045, I2=96%). ICU admission reported high percentage in infected patients (OR =4.87, 95% CI: 3.08-7.71; p<0.0001, I2=93%), we found that obstetric complication in subgroup (OR =1.31, 95% CI: 0.13-1.52; p<0.0003,I2=54%) and mortality (OR =17.41, 95% CI: 11.04-27.46; p<0.0001, I2=0%) less in non infected patients. Pregnancy with infected COVID-19 has high percentage of mortality and morbidity events. Infected and non infected patients has equal chance for vaginal or caesarian delivery.

References


C. Wang, P. W. Horby, F. G. Hayden, and G. F. Gao, “A novel coronavirus outbreak of global health concern,” Lancet, vol. 395, no. 10223, pp. 470–473, Feb. 2020, doi: 10.1016/S0140-6736(20)30185-9.

P. M. M. de Souza et al., “COVID-19 Home Deaths without Medical Assistance in Northeastern Brazil,” Am. J. Trop. Med. Hyg., vol. 104, no. 2, pp. 514–518, Feb. 2021, doi: 10.4269/ajtmh.20-1210.

S. Ellington et al., “Characteristics of Women of Reproductive Age With Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status—United States, January 22–June 7, 2020,” Obstet. Gynecol. Surv., vol. 75, no. 11, pp. 664–666, Nov. 2020, doi: 10.1097/01.ogx.0000721400.07132.fc.

G. Favre, L. Pomar, D. Musso, and D. Baud, “2019-nCoV epidemic: what about pregnancies?,” Lancet, vol. 395, no. 10224, p. e40, Feb. 2020, doi: 10.1016/S0140-6736(20)30311-1.

D. A. Schwartz and A. L. Graham, “Potential Maternal and Infant Outcomes from Coronavirus 2019-nCoV (SARS-CoV-2) Infecting Pregnant Women: Lessons from SARS, MERS, and Other Human Coronavirus Infections,” Viruses, vol. 12, no. 2, p. 194, Feb. 2020, doi: 10.3390/v12020194.

M. J. Page et al., “The PRISMA 2020 statement: an updated guideline for reporting systematic reviews,” BMJ, vol. 372, p. n71, Mar. 2021, doi: 10.1136/bmj.n71.

W. J. J. Gierisch JM, Beadles C, Shapiro A, McDuffie JR, Cunningham N, Bradford D, Strauss J, Callahan M, Chen M, Hemminger A, Kosinski A, Nagi A, “APPENDIX B. NEWCASTLE-OTTAWA SCALE CODING MANUAL FOR COHORT STUDIES,” in Health Disparities in Quality Indicators of Healthcare Among Adults with Mental Illness, Washington (DC): Department of Veterans Affairs Health Services Research & Development Service (US), 2014, pp. 79–80.

CEBM Levels of Evidence Working Group, “The Oxford 2011 Levels of Evidence,” Oxford Centre for Evidence-Based Medicine. https://www.cebm.ox.ac.uk/resources/levels-of-evidence/ocebm-levels-of-evidence (accessed Jan. 24, 2021).

E. H. Adhikari et al., “Pregnancy Outcomes Among Women With and Without Severe Acute Respiratory Syndrome Coronavirus 2 Infection,” JAMA Netw. Open, vol. 3, no. 11, p. e2029256, Nov. 2020, doi: 10.1001/jamanetworkopen.2020.29256.

J. Chinn et al., “Characteristics and Outcomes of Women With COVID-19 Giving Birth at US Academic Centers During the COVID-19 Pandemic,” JAMA Netw. Open, vol. 4, no. 8, p. e2120456, Aug. 2021, doi: 10.1001/jamanetworkopen.2021.20456.

N. Hcini et al., “Maternal, fetal and neonatal outcomes of large series of SARS-CoV-2 positive pregnancies in peripartum period: A single-center prospective comparative study,” Eur. J. Obstet. Gynecol. Reprod. Biol., vol. 257, no. January, pp. 11–18, Feb. 2021, doi: 10.1016/j.ejogrb.2020.11.068.

J. Y. Ko et al., “Adverse Pregnancy Outcomes, Maternal Complications, and Severe Illness Among US Delivery Hospitalizations With and Without a Coronavirus Disease 2019 (COVID-19) Diagnosis,” Clin. Infect. Dis., vol. 73, no. Supplement_1, pp. S24–S31, Jul. 2021, doi: 10.1093/cid/ciab344.

O. Martinez-Perez et al., “The association between SARS-CoV-2 infection and preterm delivery: a prospective study with a multivariable analysis,” BMC Pregnancy Childbirth, vol. 21, no. 1, p. 273, Dec. 2021, doi: 10.1186/s12884-021-03742-4.

M. Prabhu et al., “Pregnancy and postpartum outcomes in a universally tested population for SARS‐CoV‐2 in New York City: a prospective cohort study,” BJOG An Int. J. Obstet. Gynaecol., vol. 127, no. 12, pp. 1548–1556, Nov. 2020, doi: 10.1111/1471-0528.16403.

H. A. Steffen et al., “SARS-CoV-2 Infection during Pregnancy in a Rural Midwest All-delivery Cohort and Associated Maternal and Neonatal Outcomes,” Am. J. Perinatol., vol. 38, no. 06, pp. 614–621, May 2021, doi: 10.1055/s-0041-1723938.

I. Gurol-Urganci et al., “Maternal and perinatal outcomes of pregnant women with SARS-CoV-2 infection at the time of birth in England: national cohort study,” Am. J. Obstet. Gynecol., vol. 225, no. 5, pp. 522.e1-522.e11, Nov. 2021, doi: 10.1016/j.ajog.2021.05.016.

J. Villar et al., “Maternal and Neonatal Morbidity and Mortality Among Pregnant Women With and Without COVID-19 Infection,” JAMA Pediatr., vol. 175, no. 8, p. 817, Aug. 2021, doi: 10.1001/jamapediatrics.2021.1050.

S. Eguchi, T. Kawai, R. Scalia, and V. Rizzo, “Understanding Angiotensin II Type 1 Receptor Signaling in Vascular Pathophysiology,” Hypertension, vol. 71, no. 5, pp. 804–810, May 2018, doi: 10.1161/HYPERTENSIONAHA.118.10266.

Y. Jing et al., “Potential influence of COVID-19/ACE2 on the female reproductive system,” Mol. Hum. Reprod., vol. 26, no. 6, pp. 367–373, Jun. 2020, doi: 10.1093/molehr/gaaa030.

M. B. Cavalcante, C. T. de M. B. Cavalcante, M. Sarno, R. Barini, and J. Kwak-Kim, “Maternal immune responses and obstetrical outcomes of pregnant women with COVID-19 and possible health risks of offspring,” J. Reprod. Immunol., vol. 143, no. January, p. 103250, Feb. 2021, doi: 10.1016/j.jri.2020.103250.

A. K. Malinowski, A. Noureldin, and M. Othman, “COVID-19 susceptibility in pregnancy: Immune/inflammatory considerations, the role of placental ACE-2 and research considerations,” Reprod. Biol., vol. 20, no. 4, pp. 568–572, Dec. 2020, doi: 10.1016/j.repbio.2020.10.005.

J. Cai et al., “Cesarean Section or Vaginal Delivery to Prevent Possible Vertical Transmission From a Pregnant Mother Confirmed With COVID-19 to a Neonate: A Systematic Review,” Front. Med., vol. 8, no. February, pp. 1–12, Feb. 2021, doi: 10.3389/fmed.2021.634949.

M. L. Debrabandere, D. C. Farabaugh, and C. Giordano, “A Review on Mode of Delivery during COVID-19 between December 2019 and April 2020,” Am. J. Perinatol., vol. 38, no. 04, pp. 332–341, Mar. 2021, doi: 10.1055/s-0040-1721658.

P. Giaxi, E. Maniatelli, and V. Vivilaki, “Evaluation of mode of delivery in pregnant women infected with COVID-19,” Eur. J. Midwifery, vol. 4, no. July, pp. 823–829, Jul. 2020, doi: 10.18332/ejm/123888.

E. Kordzadeh-Kermani, H. Khalili, and I. Karimzadeh, “Pathogenesis, clinical manifestations and complications of coronavirus disease 2019 (COVID-19),” Future Microbiol., vol. 15, no. 13, pp. 1287–1305, Sep. 2020, doi: 10.2217/fmb-2020-0110.

M. J. Blitz et al., “Intensive care unit admissions for pregnant and nonpregnant women with coronavirus disease 2019,” Am. J. Obstet. Gynecol., vol. 223, no. 2, pp. 290–291, Aug. 2020, doi: 10.1016/j.ajog.2020.05.004.

N. Vousden et al., “The incidence, characteristics and outcomes of pregnant women hospitalized with symptomatic and asymptomatic SARS-CoV-2 infection in the UK from March to September 2020: A national cohort study using the UK Obstetric Surveillance System (UKOSS),” PLoS One, vol. 16, no. 5, p. e0251123, May 2021, doi: 10.1371/journal.pone.0251123.

J. S. Brandt et al., “Epidemiology of coronavirus disease 2019 in pregnancy: risk factors and associations with adverse maternal and neonatal outcomes,” Am. J. Obstet. Gynecol., vol. 224, no. 4, pp. 389.e1-389.e9, Apr. 2021, doi: 10.1016/j.ajog.2020.09.043.

Z. Y. Tambawala, Z. T. Hakim, L. K. Hamza, and M. Al Rayes, “Successful management of severe acute respiratory distress syndrome due to COVID-19 with extracorporeal membrane oxygenation during mid-trimester of pregnancy,” BMJ Case Rep., vol. 14, no. 2, p. e240823, Feb. 2021, doi: 10.1136/bcr-2020-240823.

P. Dashraath et al., “Coronavirus disease 2019 (COVID-19) pandemic and pregnancy,” Am. J. Obstet. Gynecol., vol. 222, no. 6, pp. 521–531, Jun. 2020, doi: 10.1016/j.ajog.2020.03.021.

E. D. Shanes, L. B. Mithal, S. Otero, H. A. Azad, E. S. Miller, and J. A. Goldstein, “Placental Pathology in COVID-19,” Am. J. Clin. Pathol., vol. 154, no. 1, pp. 23–32, Jun. 2020, doi: 10.1093/ajcp/aqaa089.

K. Narang et al., “SARS-CoV-2 Infection and COVID-19 During Pregnancy: A Multidisciplinary Review,” Mayo Clin. Proc., vol. 95, no. 8, pp. 1750–1765, Aug. 2020, doi: 10.1016/j.mayocp.2020.05.011.

M. Gulersen, M. J. Blitz, B. Rochelson, M. Nimaroff, W. Shan, and E. Bornstein, “Clinical Implications of SARS-CoV-2 Infection in the Viable Preterm Period,” Am. J. Perinatol., vol. 37, no. 11, pp. 1077–1083, Sep. 2020, doi: 10.1055/s-0040-1713851.

H. Hosier et al., “SARS–CoV-2 infection of the placenta,” J. Clin. Invest., vol. 130, no. 9, pp. 4947–4953, Aug. 2020, doi: 10.1172/JCI139569.

M. Bos et al., “Clinical outcomes in chronic intervillositis of unknown etiology,” Placenta, vol. 91, pp. 19–23, Feb. 2020, doi: 10.1016/j.placenta.2020.01.001.

C. Nowak et al., “Perinatal prognosis of pregnancies complicated by placental chronic villitis or intervillositis of unknown etiology and combined lesions: About a series of 178 cases,” Placenta, vol. 44, pp. 104–108, Aug. 2016, doi: 10.1016/j.placenta.2016.04.017.

D. Baud et al., “Second-Trimester Miscarriage in a Pregnant Woman With SARS-CoV-2 Infection,” JAMA, vol. 323, no. 21, p. 2198, Jun. 2020, doi: 10.1001/jama.2020.7233.

S. A. Taghavi et al., “Obstetric, maternal, and neonatal outcomes in COVID-19 compared to healthy pregnant women in Iran: a retrospective, case-control study,” Middle East Fertil. Soc. J., vol. 26, no. 1, p. 17, Dec. 2021, doi: 10.1186/s43043-021-00059-2.

M. J. Wang, M. Schapero, R. Iverson, and C. D. Yarrington, “Obstetric Hemorrhage Risk Associated with Novel COVID-19 Diagnosis from a Single-Institution Cohort in the United States,” Am. J. Perinatol., vol. 37, no. 14, pp. 1411–1416, Dec. 2020, doi: 10.1055/s-0040-1718403.

J. Liao, X. He, Q. Gong, L. Yang, C. Zhou, and J. Li, “Analysis of vaginal delivery outcomes among pregnant women in Wuhan, China during the COVID‐19 pandemic,” Int. J. Gynecol. Obstet., vol. 150, no. 1, pp. 53–57, Jul. 2020, doi: 10.1002/ijgo.13188.

L. Zhang et al., “[Analysis of the pregnancy outcomes in pregnant women with COVID-19 in Hubei Province].,” Zhonghua Fu Chan Ke Za Zhi, vol. 55, no. 3, pp. 166–171, Mar. 2020, doi: 10.3760/cma.j.cn112141-20200218-00111.

S. Hantoushzadeh et al., “Maternal death due to COVID-19,” Am. J. Obstet. Gynecol., vol. 223, no. 1, pp. 109.e1-109.e16, Jul. 2020, doi: 10.1016/j.ajog.2020.04.030.

K. S. Hazari et al., “Covid-19 infection in pregnant women in Dubai: a case-control study,” BMC Pregnancy Childbirth, vol. 21, no. 1, p. 658, Dec. 2021, doi: 10.1186/s12884-021-04130-8.

E. S. Karabulut Keklik, H. Dal, and Ş. Bozok, “Cytokine Hemoadsorption in the Management of a Pregnant Woman with COVID-19 Pneumonia: Case Report,” SN Compr. Clin. Med., vol. 2, no. 11, pp. 2376–2380, Nov. 2020, doi: 10.1007/s42399-020-00508-5.

R. Lu et al., “Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding,” Lancet, vol. 395, no. 10224, pp. 565–574, Feb. 2020, doi: 10.1016/S0140-6736(20)30251-8.

E. M. Lokken et al., “Disease severity, pregnancy outcomes, and maternal deaths among pregnant patients with severe acute respiratory syndrome coronavirus 2 infection in Washington State,” Am. J. Obstet. Gynecol., vol. 225, no. 1, pp. 77.e1-77.e14, Jul. 2021, doi: 10.1016/j.ajog.2020.12.1221.

B. R. Mercedes et al., “New-onset myocardial injury in pregnant patients with coronavirus disease 2019: a case series of 15 patients,” Am. J. Obstet. Gynecol., vol. 224, no. 4, pp. 387.e1-387.e9, Apr. 2021, doi: 10.1016/j.ajog.2020.10.031.

S. L. Pachtman Shetty, N. Meirowitz, M. J. Blitz, T. Gadomski, and C. R. Weinberg, “Myocardial injury associated with coronavirus disease 2019 in pregnancy,” Am. J. Obstet. Gynecol., vol. 224, no. 2, pp. 229–232, Feb. 2021, doi: 10.1016/j.ajog.2020.10.014.

A. Juusela, M. Nazir, and M. Gimovsky, “Two cases of coronavirus 2019–related cardiomyopathy in pregnancy,” Am. J. Obstet. Gynecol. MFM, vol. 2, no. 2, p. 100113, May 2020, doi: 10.1016/j.ajogmf.2020.100113.

R. Kumar et al., “SARS-CoV-2 infection during pregnancy and pregnancy-related conditions: Concerns, challenges, management and mitigation strategies–a narrative review,” J. Infect. Public Health, vol. 14, no. 7, pp. 863–875, Jul. 2021, doi: 10.1016/j.jiph.2021.04.005.




DOI: http://doi.org/10.11591/ijphs.v11i4.21769

Refbacks



International Journal of Public Health Science (IJPHS)
p-ISSN: 2252-8806, e-ISSN: 2620-4126

View IJPHS Stats

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.